Player Avatar zzlangerhans (99.81) Submitted: 7/18/2011 6:48:22 PM : Underperform Start Price: $9.00 INFI Score: +4.77

Sometimes I like to play a mental exercise with biotech stocks. I call it Then and Now. I look at the stock now and a few months ago and try and figure out what justified a massive change in the share price. Let's play Then and Now with Infinity.

Then (March 16, 2011): Share price 5.33. Cash 101M. Controlled phase II trials of oral Hedgehog inhibitor IPI-926 in advanced chondrosarcoma and in metastatic pancreatic cancer have recently been initiated. IPI-926 is partnered with Purdue/Mundipharma with a funding commitment of 85M in 2011 and 110M in 2012. Phase II studies of oral FAAH inhibitor IPI-940 for pain as well as initial clinical trials of oral p3kinase inhibitor IPI-145 are planned for later this year. Phase I data for Hsp90 inbhibitor retaspimycin with docetaxel in solid tumors will also be released later this year.

Now (July 18, 2011): Share price 9.0. Cash 91M. Enrollment in phase II trial of IPI-926 and gemcitabine in pancreatic cancer is expected to be complete by the end of 2011. A phase I trial of IPI-926 and Erbitux in advanced head and neck cancer has been initiated at the University of Colorado as part of an investigator-sponsored trial program. The phase II trial of IPI-926 in advanced chondrosarcoma continues to enroll, and a phase II trial of IPI-926 in myelofibrosis will be initiated later this quarter. In 5/11 company initiated a phase II trial of retaspimycin with docetaxel in lung cancer.

As far as I can tell there isn't much in the way of elapsed or upcoming catalysts to explain a 70% increase in share price from recent lows over the last four months. There hasn't even been a coordinated pumping effort on Seeking Alpha. So what accounts for it? Stochastic price movement? Irrational speculation? Low float manipulation? Or a combination of the above? In the spirit of Taco Bell, I'll call it stochirrapulation. Infinity hasn't won my confidence with a series of failures in their Hsp90 inhibitor program and I don't have any strong reason to have faith in their Hedgehog inhibitor program. I'm betting this move is pure stochirrapulation.

Member Avatar Kvedarna (99.51) Submitted: 7/26/2011 12:14:08 PM
Recs: 0

Your ideas and your comments are much appreciated.

Featured Broker Partners